LAUSR

BACKGROUND Hypogammaglobulinemia (HGG) is a complication of solid organ transplantation leading to increased risk of infections. Intravenous immunoglobulin G (IVIG) replacement in patients with HGG may be able to reduce risk and morbidity associated with infection; however, there is scarce data about IVIG in mild to moderate HGG (IgG 400-700 mg/dL) and heart transplant recipients. METHODS A single center, retrospective study was performed in heart transplant recipients with mild (IgG 500-700 mg/dL) to moderate (IgG 400-499 mg/dL) HGG in the presence of an infection. RESULTS Forty-two patients were included in this study; 19 patients (45.2%) received IVIG and 23 (54.8%) patients did not. Patients in the IVIG group received on average one dose of IVIG at 0.5 g/kg. No differences in incidence of new infection at 3 months (26.3% vs 17.4%; p = 0.71) and 6 months (42.1% vs 34.8%; p = 0.63) were observed between the IVIG and non-IVIG groups. Infections based on mild or moderate HGG also had no differences at 3 and 6 months. CONCLUSION Our findings suggest that a single infusion of IVIG in mild to moderate HGG may have little to no benefit in reducing incidence of new infections. Larger prospective studies are needed to confirm these findings. This article is protected by copyright. All rights reserved.